Skip to main content

Table 1 Characteristics of the 7 included studies

From: Preoperative short-course radiotherapy followed by consolidation chemotherapy for treatment with locally advanced rectal cancer: a meta-analysis

References

Study design

Sample size

Intervention

Follow-up time (months)

Outcomes

SCRT/CCT

LCCRT

Markovina et al. [20]

Prospective study

138

25 Gy in 5 fractions, 4 cycles FOLFOX, TME

median 45 Gy in 25 fractions with concurrent CT, TME

49.4/54.3

OS, DFS, LRR, DMR, pCR rate, ypTNM, downstaging, sphincter preserve rate, R0 resection rate, toxicity

Chung et al. [21]

Retrospective study

72

25 Gy in 5 fractions with concurrent CT, 3 cycles CT, TME

50.4 Gy in 28 fractions with concurrent CT, TME

25

OS, DFS, LRR, DMR, pCR rate, downstaging, sphincter preserve rate, R0 resection rate, toxicity

Ciseł et al. [17]

Randomized controlled trials

515

25 Gy in 5 fractions, 3 cycles FOLFOX4, TME

50.4 Gy in 28 fractions with concurrent CT, TME

84.0

OS, DFS, LRR, DMR, pCR rate, ypTNM, sphincter preserve rate, R0 resection rate, toxicity

Bahadoer et al. [9]

Randomized controlled trials

912

25 Gy in 5 fractions, 6 cycles CAPOX or 9 cycles FOLFOX, TME

50–50.4 Gy in 25–28 fractions with concomitant CT, TME

55.2

OS, DFS, LRR, DMR, pCR rate, ypTNM, sphincter preserve rate, R0 resection rate, toxicity

Thakur et al. [22]

Prospective study

28

25 Gy in 5 fractions, 2 cycles CT, TME

45 Gy in 25 fractions with concurrent CT, TME

22.6

OS, DFS, LRR, DMR, pCR rate, downstaging, sphincter preserve rate, R0 resection rate, toxicity

Aghili et al. [19]

Prospective study

60

25 Gy in 5 fractions with concurrent XELOX, 3–4 weeks XELOX, TME

50–50.4 Gy in 25–28 fractions with concomitant CT, 3–4 weeks XELOX, TME

18

pCR rate, downstaging, sphincter preserve rate, R0 resection rate, toxicity

Chakrabarti et al. [18]

Randomized controlled trials

140

25 Gy in 5 fractions, 2 cycles XELOX, TME

50–50.4 Gy in 25–28 fractions with concomitant CT, TME

N/A

pCR rate, downstaging, sphincter preserve rate, R0 resection rate, toxicity

  1. SCRT/CCT, short-course radiotherapy followed by consolidation chemotherapy; LCCRT, long-course chemoradiotherapy; CT, chemotherapy; TME, total mesorectal excision; OS, overall survival; DFS, disease-free survival; LR: local recurrence; DM, distal metastasis rate; pCR, pathologic complete response; ypTNM, adjuvant pathologic staging; N/A, not available